BullFrog AI’s VP Artificial Intelligence to Present at Google’s Cancer AI Symposium
BullFrog AI (NASDAQ: BFRG; BFRGW) announced that its VP of Artificial Intelligence, Dr. Enrique García-Rivera, will present at Google's inaugural Cancer AI Symposium on October 30, 2024, in Boston. The presentation will showcase BullFrog AI's use of AI in drug discovery and development, focusing on their proprietary bfLEAP™ platform. This platform integrates multimodal biological data to accelerate drug development, particularly in cancer research.
Dr. García-Rivera will highlight the company's collaboration with the Lieber Institute for Brain Development, demonstrating bfLEAP™'s versatility across various therapeutic areas. He will also introduce BullFrog AI's novel 'AlgoLLM' system for gene prioritization, which uses large language models to streamline the discovery of actionable insights in neuropsychiatric disorders and other diseases.
BullFrog AI (NASDAQ: BFRG; BFRGW) ha annunciato che il suo VP di Intelligenza Artificiale, il Dr. Enrique García-Rivera, presenterà al simposio inaugurale sull'AI per il cancro di Google il 30 ottobre 2024, a Boston. La presentazione mostrerà come BullFrog AI utilizzi l'AI nella scoperta e nello sviluppo di farmaci, concentrandosi sulla loro piattaforma proprietaria bfLEAP™. Questa piattaforma integra dati biologici multimodali per accelerare lo sviluppo dei farmaci, in particolare nella ricerca sul cancro.
Il Dr. García-Rivera metterà in evidenza la collaborazione dell'azienda con l'Istituto Lieber per lo Sviluppo del Cervello, dimostrando la versatilità di bfLEAP™ in vari ambiti terapeutici. Introdurrà anche il nuovo sistema 'AlgoLLM' di BullFrog AI per la priorizzazione dei geni, che utilizza modelli linguistici di grandi dimensioni per semplificare la scoperta di intuizioni praticabili nei disturbi neuropsichiatrici e in altre malattie.
BullFrog AI (NASDAQ: BFRG; BFRGW) anunció que su VP de Inteligencia Artificial, el Dr. Enrique García-Rivera, presentará en el simposio inaugural de AI sobre el cáncer de Google el 30 de octubre de 2024, en Boston. La presentación destacará el uso de la IA por parte de BullFrog AI en el descubrimiento y desarrollo de medicamentos, centrándose en su plataforma propietaria bfLEAP™. Esta plataforma integra datos biológicos multimodales para acelerar el desarrollo de medicamentos, especialmente en la investigación del cáncer.
El Dr. García-Rivera resaltará la colaboración de la compañía con el Instituto Lieber para el Desarrollo del Cerebro, demostrando la versatilidad de bfLEAP™ en diversas áreas terapéuticas. También presentará el novedoso sistema 'AlgoLLM' de BullFrog AI para la priorización de genes, que emplea modelos de lenguaje de gran tamaño para simplificar el descubrimiento de información procesable en trastornos neuropsiquiátricos y otras enfermedades.
BullFrog AI (NASDAQ: BFRG; BFRGW)는 자사의 인공지능 부사장인 엔리케 가르시아-리베라 박사가 2024년 10월 30일 보스턴에서 구글의 첫 번째 암 AI 심포지엄에서 발표할 것이라고 발표했습니다. 발표는 BullFrog AI가 약물 발견과 개발에 AI를 어떻게 활용하는지를 보여주며, 그들의 독점 플랫폼인 bfLEAP™에 중점을 둘 것입니다. 이 플랫폼은 다중 모드 생물학적 데이터를 통합하여 약물 개발을 가속화하는 데 특히 암 연구에서 중요한 역할을 합니다.
가르시아-리베라 박사는 뇌 발달을 위한 리버 연구소와의 협업을 강조하며, bfLEAP™의 다양한 치료 분야에서의 다재다능함을 보여줄 것입니다. 또한, BullFrog AI의 새로운 유전자 우선순위 지정 시스템인 'AlgoLLM'을 소개할 예정이며, 이는 대규모 언어 모델을 사용하여 신경 정신 질환 및 기타 질병에서 실용적인 통찰력을 발견하는 과정을 간소화합니다.
BullFrog AI (NASDAQ: BFRG; BFRGW) a annoncé que son VP de l'Intelligence Artificielle, le Dr Enrique García-Rivera, présentera lors du premier symposium sur l'IA du cancer de Google le 30 octobre 2024 à Boston. La présentation mettra en avant l'utilisation de l'IA par BullFrog AI dans la découverte et le développement de médicaments, en se concentrant sur leur plateforme propriétaire bfLEAP™. Cette plateforme intègre des données biologiques multimodales pour accélérer le développement de médicaments, en particulier dans la recherche sur le cancer.
Le Dr García-Rivera soulignera la collaboration de l'entreprise avec l'Institut Lieber pour le Développement du Cerveau, démontrant la polyvalence de bfLEAP™ dans divers domaines thérapeutiques. Il présentera également le nouveau système 'AlgoLLM' de BullFrog AI pour la priorisation des gènes, qui utilise des modèles linguistiques de grande taille pour simplifier la découverte d'informations exploitables dans les troubles neuropsychiatriques et d'autres maladies.
BullFrog AI (NASDAQ: BFRG; BFRGW) gab bekannt, dass der VP für Künstliche Intelligenz, Dr. Enrique García-Rivera, am 30. Oktober 2024 auf dem ersten Krebs-AI-Symposium von Google in Boston sprechen wird. Die Präsentation wird die Verwendung von KI durch BullFrog AI in der Arzneimittelentdeckung und -entwicklung zeigen und sich auf die proprietäre bfLEAP™-Plattform konzentrieren. Diese Plattform integriert multimodale biologische Daten, um die Arzneimittelentwicklung, insbesondere in der Krebsforschung, zu beschleunigen.
Dr. García-Rivera wird die Zusammenarbeit des Unternehmens mit dem Lieber Institute for Brain Development hervorheben und die Vielseitigkeit von bfLEAP™ in verschiedenen therapeutischen Bereichen demonstrieren. Er wird auch das neuartige 'AlgoLLM'-System von BullFrog AI zur Priorisierung von Genen vorstellen, das große Sprachmodelle nutzt, um die Entdeckung umsetzbarer Erkenntnisse bei neuropsychiatrischen Störungen und anderen Krankheiten zu vereinfachen.
- Presentation at Google's prestigious Cancer AI Symposium enhances company visibility
- Showcasing proprietary bfLEAP™ platform demonstrates technological leadership in AI-driven drug development
- Collaboration with Lieber Institute for Brain Development highlights platform versatility
- Introduction of novel 'AlgoLLM' system for gene prioritization shows continued innovation
- None.
GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its VP Artificial Intelligence, Enrique García-Rivera, Ph.D., will present at Google’s inaugural Cancer AI Symposium on October 30, 2024, at the Boston Center for the Arts.
Dr. García-Rivera’s presentation will showcase BullFrog AI’s groundbreaking use of artificial intelligence in drug discovery and development. Highlighting the Company’s proprietary bfLEAP™ platform, the presentation will explore how multimodal biological data—including genomics, transcriptomics, and clinical data—are integrated to accelerate the drug development process.
A key aspect of the presentation will be how bfLEAP™ is applied to cancer research, leveraging AI to identify complex biological patterns that contribute to disease progression and treatment resistance. Dr. García-Rivera will also reference BullFrog AI's collaboration with the Lieber Institute for Brain Development as a prime example of how bfLEAP™ is being utilized across various therapeutic areas. The collaboration, which focuses on neurological disorders such as bipolar disorder, underscores the platform's versatility and potential to drive innovation across multiple domains, including cancer.
Dr. García-Rivera will also introduce BullFrog AI's novel "AlgoLLM" system for gene prioritization, which revolutionizes the identification of high-priority targets in drug development by harnessing large language models. This innovative AI tool is critical for streamlining the discovery of actionable insights in neuropsychiatric disorders and other diseases, advancing the Company’s mission to develop more effective and personalized treatments.
About BullFrog AI
BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
For more information visit BullFrog AI at: https://bullfrogai.com
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com
FAQ
When and where will BullFrog AI (BFRG) present at Google's Cancer AI Symposium?
What will BullFrog AI (BFRG) showcase at the Google Cancer AI Symposium?
What is BullFrog AI's (BFRG) new gene prioritization system called?
What collaboration will BullFrog AI (BFRG) highlight in its presentation?
